Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
agricultural and biological sciences
Molecular and biological characterization of human monoclonal antibodies binding to the spike and nucleocapsid proteins of severe acute respiratory syndrome coronavirus
Journal of Virology, Volume 79, No. 3, Year 2005
Notification
URL copied to clipboard!
Description
Human monoclonal antibodies (MAbs) were selected from semisynthetic antibody phage display libraries by using whole irradiated severe acute respiratory syndrome (SARS) coronavirus (CoV) virions as target. We identified eight human MAbs binding to virus and infected cells, six of which could be mapped to two SARS-CoV structural proteins: the nucleocapsid (N) and spike (S) proteins. Two MAbs reacted with N protein. One of the N protein MAbs recognized a linear epitope conserved between all published human and animal SARS-CoV isolates, and the other bound to a nonlinear N epitope. These two N MAbs did not compete for binding to SARS-CoV. Four MAbs reacted with the S glycoprotein, and three of these MAbs neutralized SARS-CoV in vitro. All three neutralizing anti-S MAbs bound a recombinant S1 fragment comprising residues 318 to 510, a region previously identified as the SARS-CoV S receptor binding domain; the nonneutralizing MAb did not. Two strongly neutralizing anti-S1 MAbs blocked the binding of a recombinant S fragment (residues 1 to 565) to SARS-CoV-susceptible Vero cells completely, whereas a poorly neutralizing S1 MAb blocked binding only partially. The MAb ability to block S1-receptor binding and the level of neutralization of the two strongly neutralizing S1 MAbs correlated with the binding affinity to the S1 domain. Finally, epitope mapping, using recombinant S fragments (residues 318 to 510) containing naturally occurring mutations, revealed the importance of residue N479 for the binding of the most potent neutralizing MAb, CR3014. The complete set of SARS-CoV MAbs described here may be useful for diagnosis, chemoprophylaxis, and therapy of SARS-CoV infection and disease. Copyright © 2005, American Society for Microbiology. All Rights Reserved.
Authors & Co-Authors
Ter Meulen, Jan H.
Netherlands, Leiden
Crucell nv
Jongeneelen, Mandy A.C.
Netherlands, Leiden
Crucell nv
Throsby, Mark
Netherlands, Leiden
Crucell nv
Marissen, Wilfred E.
Netherlands, Leiden
Crucell nv
Gelderblom, Hans R.
Germany, Berlin
Robert Koch Institute
Martina, Byron E.E.
Netherlands, Rotterdam
Erasmus Mc
Osterhaus, Albert D.M.E.
Netherlands, Rotterdam
Erasmus Mc
Preiser, Wolfgang
Germany, Frankfurt am Main
Goethe-universität Frankfurt am Main
Doérr, Hans Wilhelm
Germany, Frankfurt am Main
Goethe-universität Frankfurt am Main
de Kruif, John
Netherlands, Leiden
Crucell nv
Goudsmit, Jaap
Netherlands, Leiden
Crucell nv
Statistics
Citations: 137
Authors: 11
Affiliations: 4
Identifiers
Doi:
10.1128/JVI.79.3.1635-1644.2005
ISSN:
0022538X
Research Areas
Covid